HBVS

AcronymDefinition
HBVSHepatitis B Virus Surface
References in periodicals archive ?
Hepatitis B virus (HBV) belongs to the family Hepadnaviridae, members of which constitute 2 major extant genera: Orthohepadnavirus, which infect mammals, and Avihepadnavirus, which infect birds (7).
We describe a new avian HBV causing severe hepatitis in the elegant-crested tinamou (Eudromia elegans), a member of the ancient group of birds the Palaeognathae, which includes emus (Dromaius novaehollandiae) and ostriches (Struthio spp.).
However, there can be failures in some cases such as emerging anti-HBs-escape mutant viruses, patients with compromised immune-response or heterologous HBV genotypes.
The former infects mammals and is represented by: HBV (Hepatitis B Virus), which infects humans; viruses similar to HBV (such as woolly monkey HBV and orangutan-HBV for example), which infect non-human primates; Woodchuck hepatitis virus (WHV) that causes hepatitis in woodchucks, and Ground squirrel hepatitis virus (GSHV) causing hepatitis in squirrels.
For a fixed n, [[alpha].sub.n] := [{[[alpha].sub.n,k]}.sup.[infinity].sub.k=0] of nonnegative numbers tending to zero is called of Head bounded variation, or briefly [[alpha].sub.n][member of] HBVS, if there is a constant C([[alpha].sub.n]) only depend on [[alpha].sub.n] such that
It is clear that every monotone increasing sequence is {[[lambda].sub.n]} HBVS, but not conversely.
In 104 of the hospitals, at least one registered nurse was involved in the process, and at least one pharmacist was involved in 10 hospital HBV policy developments.
For 203 nursery directors who knew about the Centers for Disease Control and Prevention and American Academy of Pediatrics' July 1999 recommendation to postpone the first dose of HBV for low-risk infants from birth until 2-6 months of age, the most common initial sources of knowledge were the AAP (27%) and pharmaceutical companies (16%).
Dicerna believes that its current cash, cash-equivalents, and held-to-maturity investments will be sufficient to fund the execution of its current clinical and operating plan beyond 2020, which includes advancing DCR-PHXC through late-stage clinical development and regulatory filing, completing the proof-of-concept study of DCR-HBVS in participants with HBV, and advancing the Company's DCR-A1AT program through the initial clinical study.
HBV infection embraces wide spectrum of liver diseases including acute and chronic hepatitis, with liver cirrhosis and hepatocellular carcinoma (HCC) being the frequent long-term complications.
HBV infection is believed to be common in Tanzania where its appropriate diagnosis and conventional management are uncertain.
HBV has been infecting humans for a long time; thus, it is possible that genotypic or phenotypic changes have occurred over time, especially since the introduction of HBV vaccine and antiviral drugs.